In colorectal cancer patients, not only was there differential expressions of PERK and HSPA5 in tumor and metastatic tissues but also single nucleotide polymorphisms were predicted to contribute to genetic variants that may influence the susceptibility of targeted UPR agents [215]. The gene discussed is HSPA5; the disease is neoplasm.